Ju, Nan
Shimamura, Munehisa
Hayashi, Hiroki
Ikeda, Yuka
Yoshida, Shota
Nakamura, Ayumi
Morishita, Ryuichi
Rakugi, Hiromi http://orcid.org/0000-0001-6508-4338
Nakagami, Hironori
Article History
Received: 13 February 2019
Accepted: 30 September 2019
First Online: 28 October 2019
Competing interests
: A patent application has been filed for the MHPs (Application No. 2015-102502 and PCT/JP2016/064446; M.S., H.N. and R.M.). The Department of Clinical Gene Therapy is financially supported by Novartis, AnGes, Shionogi, Boeringher, Fancl, Saisei Mirai Clinics, Rohto, and Funpep. The Department of Health Development and Medicine is financially supported by AnGes, Funpep, and DAICEL. R.M. is a founder and shareholder of AnGes and a former board member. R.M. is also a shareholder of Funpep. M.S. and H.N. are shareholders of MH Peptide. This company has a contract for priority rights of negotiation regarding the MHP-1 patent with Osaka University. There are no conflicts of interest between any authors and MH Peptide, as adjudicated by the Conflict of Interest Committee at Osaka University. The company was not involved in the “design and conduct of the study,” “collection, management, analysis, and interpretation of data,” “preparation, review, or approval of the manuscript,” or the “decision to submit the manuscript for publication”.